Home
About BCG
Contact Us
Locations
Services
Areas of Expertise
Regulatory Library
Newsletter Archive
Useful Web Links
Presentations
 

 

 

 

 

 

 

 

 


EDUCATION:

M.D. The Johns Hopkins School of Medicine, Baltimore, MD (1984)
B.A. German and Biology, Middlebury College, Middlebury, VT (1980)

EXPERIENCE:

CURRENT
POSITION Feb. 2008 to present:
 

Senior Clinical Consultant, Biologics Consulting Group, Inc., Chapel Hill, NC.

   
Apr. 2005 to Jan. 2008  

Vice President of Drug Development, Biolex Therapeutics, Inc., Pittsboro, NC.

Direction of pharmacology, toxicology and clinical development activities for all Biolex products including:

  • BLX-883 human interferon alpha 2b
  • Locteron (controlled-release interferon alfa 2b)
    • Responsible for developing toxicology program to support clinical development, direction of clinical trials (phases 1 and 2) and for creation of clinical development program leading to licensing of Locteron for the treatment of chronic hepatitis C.
  • BLX-155 (Plasmin).
    • Responsible for developing toxicology program to support clinical development of Plasmin in multiple indications.
    • Responsible for creating clinical strategy for licensing program for Plasmin.
    • Responsible for designing clinical trials of Plasmin in multiple indications.
  • Other Proteins:
    • Responsible for clinical evaluation of proteins for possible in-licensing or in-house development.

 

   
Sep. 2001 to Mar. 2005  

Director, Global Clinical Strategy Biologics Division, Global Strategic Marketing / Vascular, Intensive Care, Respiratory and Immunology, Bayer HealthCare, LLC, Research Triangle Park NC.

  • Global clinical strategist for Plasmin
    • Worked with marketing and opinion leaders in US, EU and Japan to identify optimal licensing indications and trial designs
    • Developed an international advisory board of experts in interventional radiology, cardiology, hematology and vascular surgery - met every 6 months
    • Obtained agreement with FDA on phase I trial design
  • Global clinical strategist for Alpha-1-Antitrypsin (AAT)
    • Developed licensing strategies for a new version of plasma-derived AAT for 2 indications: congenital AAT deficiency (intravenous) and cystic fibrosis (aerosol)
    • Wrote position paper on novel primary endpoint for licensing trial of aerosolized AAT for FDA and EMEA
    • Clinical representative on transgenic AAT collaboration with PPL, Lt
    • Designed and oversaw a phase II study of recAAT by aerosol administration in patients with congenital A1AT deficiency
    • Developed 3 expert panels and held teleconferences with FDA regarding the outcome of this trial
    • Created the Alpha-1-antitrypsin Laurell's Training Awards (ALTA) Program to bring young researchers into the field of A1AT investigation
    • Sserved as Bayer representative on the grant review committee with 5 European physician opinion leaders
    • First 2 awardees presented at Bayer-sponsored symposium at 2004 European Respiratory Society meeting in Glasgow, September, 2004
    • Director of ADAPT (Alpha-1-antitrypsin Detection and Assessment
      Programme of Therapy) involving researchers in the US and UK; d
      eveloped a registry of patients for conducting clinical trials and gathering natural history information to facilitate licensing trials in congenital AAT deficiency; held meetings every 6 months with consultants and selected Bayer representatives
    • Developed expert group for assistance in designing / selecting aerosol devices for delivering AAT by aerosol in cystic fibrosis, meetings held in May and July of 2003 and in October, 2004
  • Global clinical strategist for IGIV-C
    • Developed international advisory board of opinion leaders to assess a new indication and design a phase III clinical trial for licensing in Chronic Inflammatory Demyelinating Polyneuropathy (CIPD)
    • Worked with clinical development team in negotiations with and to gain agreement with FDA on phase III trial design in CIDP
    • Program Director: GRIP: Gamunex (IGIV-C) Research Initiative Program - to facilitate phase IV research and assess potential new indications
    • Developed North American experts group to debate options for licensing clinical trials of IVIG in the area of renal transplantation, then to design a pivotal trial
  • Global clinical strategist for Albumin
    • Developed international opinion leader / advisory committee for assessment of potential new indications for albumin and development of a clinical trials program for life-cycle management
    • Held experts meeting regarding the risks of aluminum in albumin products; led to preparation of a paper for publication
  • Global clinical strategist: Other
    • Clinical evaluator of possible pipe-line development and in-licensing of products for development - assess clinical need / feasibility of trials and licensing
   
Apr. 1999 to Sep. 2001  

Director, International Clinical Projects, Biologics Division, Bayer Corporation, Research Triangle Park, NC.

  • Planned life-cycle management programs for non-hemophilia biologics (IVIG, Alpha-1-antitrypsin [AAT] Albumin, Antithrombin III)
  • Developed licensing strategy for new indication for AT III (heparin resistance in cardiopulmonary bypass)
  • Planned clinical development for new products (Plasmin, transgenic AAT)
  • Developed budgets (out to 5 years) for clinical trials for the above programs
  • Developed regulatory licensing strategy for transgenic AAT for the treatment of congenital AAT deficiency; including presentations to FDA and EMEA
  • Worked with research and development in the assessment of potential new drugs for internal development or in-licensing.
   
May 1998 to Mar. 1999  

Associate Director, Scientific Studies, Pharmaceutical Division, Bayer Corporation, West Haven, CT.

  • Chair, Biologics Phase IV program: set up multidisciplinary internal committee to review and award grants for Phase IV research for Biologics in the US (IVIG, AAT, Kogenate, Albumin and Antithrombin III)
   
Jul 1997 to May 1998  

Associate Professor (Joint Appointment), Division of Hematology/Oncology, Department of Internal Medicine, Department of Pathology, University of Virginia, Charlottesville, Virginia.

   
Jul 1995 to May 1998  

Director, Hemostasis and Thrombosis Clinic, University of Virginia Health Sciences Center, Charlottesville, Virginia.

   
Jul 1994 to May 1998   Consultant, Veterans Administration Medical Center, Salem, Virginia.
   
May 1992 to Jun 1997   Assistant Professor (Joint Appointment), Division of Hematology/Oncology, Department of Internal Medicine, Department of Pathology, University of Virginia, Charlottesville, Virginia.
   
May 1991 to Apr. 1992  

Instructor (Joint Appointment), Division of Hematology/Oncology, Department of Internal Medicine, Department of Pathology, University of Virginia, Charlottesville, Virginia.

   
Nov. 1990 to May 1998  

Associate Director, Special Coagulation Laboratory Department of Pathology
University of Virginia Health Sciences Center, Charlottesville, Virginia.


Residency and Fellowship Training

1984 1987 Resident in Internal Medicine
The Johns Hopkins Hospital, Baltimore, MD
Program Director: Victor A. McKusick, M.D.
1987-1990 Fellow, Division of Hematology/Oncology
University of VA School of Medicine
Charlottesville, VA
Program Director: Peter J. Quesenberry, M.D.

Honors and Awards
2007 Biolex Award for Excellence
2003 PPTA Albumin Committee: Special Appreciation Award
2003 Bayer Special Recognition Award
2001 PPTA Albumin Committee: Special Appreciation Award
1984 Phi Beta Kappa - Middlebury College
1984 Summa Cum Laude - Middlebury College

Certifications and Licensures

Certifications
November, 1995 Academy of Clinical and Applied Thrombosis, Hemostasis and Vascular Medicine - Diplomate
November, 1990 American Board of Internal Medicine
Certification in Hematology
September, 1988 American Board of Internal Medicine
Certification in Internal Medicine
December, 1985 FLEX - Federation Licensing Examination

Licensure
Prior: MD, VA, Connecticut
None currently active

Clinical Activities (1992 - 1998)

  • Attending - 1-3 months per year on inpatient Hematology/Oncology Service
  • Attending - 2-4 months per year - Hematology Consultation Service
  • Attending - 12 months per year - Coagulation Consultation Service
  • Outpatient clinic two 1/2 days per week - patients with disorders of hemostasis and thrombosis, also general non-malignant Hematology
  • Bone marrow aspiration review - 2-5 months per year
  • Daily Special Coagulation Laboratory - work rounds with Clinical Pathology Residents - year-round

Teaching

December, 1997 "The Role of Hypercoagulable States in Dermatology" Dermatology Grand Rounds
November, 1997 "Role of the PT and aPTT in Interventional Radiology" Radiology Grand Rounds
November, 1997 "Update on Lupus Anticoagulant Testing" Rheumatology Grand Rounds
October, 1997 "Disorders of Hemostasis in Liver Disease" Gastroenterology/Hepatology Research Conference
October, 1997 "Approach to the Diagnosis and Management of Bleeding Disorders" Anesthesiology Grand Rounds
September, 1997 "Update on Approach to Diagnosis and Management of Bleeding Disorders" Surgery Grand Rounds
September, 1997 "Stroke and the Hypercoagulable States" Neurology Grand Rounds
September, 1997 "Approach to Diagnosis and Treatment of Inherited and Acquired Bleeding Disorders" Dentistry Grand Rounds
September, 1997 "Update on Approach to Diagnosis and Management of Bleeding Disorders" Neurosurgery Grand Rounds
March, 1997 "Diagnosis and Management of Inherited and Acquired Coagulation Disorders" Plastic Surgery Grand Rounds
September, 1996 "Outpatient Management of Deep Vein Thrombosis" Medical Grounds
August, 1996 "Emergency Room Management of Deep Vein Thrombosis" Department of Emergency Medicine Rounds
1996 - 1998 Lectures on Hemostasis, Thrombosis and Platelets: 3 hours annually, 1st year students, WV School of Osteopathic Medicine
November, 1995 "Regulation of Alpha-2-antiplasmin" Department of Pathology Research Seminar
October, 1995 "Diagnosis and Management of Bleeding Disorders" Department of Dentistry Rounds
October, 1995 "Treatment of Acquired Coagulation Disorders" Department of Anesthesiology Grand Rounds
September, 1995 "Update on Hypercoagulability: Activated Protein C Resistance" Medical Grand Rounds
September, 1995 "Clinical and Laboratory Aspects of Hemostasis" Department of Anesthesiology Grand Rounds
September, 1994 "Use of Antithrombin III Concentrates in the Management of DIC" Critical Care Grand Rounds
August, 1994 "Management of Acquired Antithrombin III Deficiency" Department of Medicine Grand Rounds
May, 1994 "Clinical Uses of Low Molecular Weight Heparins" Department of Medicine Grand Rounds
August, 1993 "The INR: International Normalized Ratio" Thoracic/Cardiovascular Surgery Rounds
June, 1993 "Lupus Anticoagulant" Lupus Clinic Conference, Rheumatology Division
February, 1993 "Introduction to the INR" INR Research Group Meeting
January, 1993 "The Hypercoagulable States" Neurology Grand Grounds
December, 1992 "Clinical and Laboratory Aspects of Hemostasis" General Surgery Grand Rounds
September, 1992 "Approach to the Bleeding Patient" Acute Care Conference for Internal Medicine Housestaff
August, 1992 "Introduction to Hemostasis" Department of Dentistry Rounds
August, 1992 "Acquired Hemophilia" Department of Medicine Grand Rounds, University of VA
August, 1992 "Introduction to Hemostasis" Lecture to Hematology/Oncology Outpatient Clinic Nursing Staff
February, 1991 "Anticoagulation and Procedures" Department of Medicine Grand Rounds, University of VA
May, 1990 "Bleeding Disorders in the ICU" Critical Care Grand Rounds, University of VA
1992 - 1998 "Introduction to Anemia." One hour lecture to 3rd year medical students; 2-3 times per year
1992 - 1998 Pathology course for second year medical students. Two to four 1-hour lectures on hemostasis and thrombosis, fibrinolysis and platelets.
1988 - 1990 Two hour lecture on "Anemia;" School of Nursing; nurse practitioner students
1988 - 1998 Physical Diagnosis, School of Medicine; 2nd year medical students; 5 two hour sessions
Spring 1989, 1990 and 1992 Physical Diagnosis Course; School of Medicine; 1st year medical students; two hours per week for six weeks
July, 1989 - May, 1998 Coagulation Conference: Departments of Pathology and Internal Medicine; one hour per week; year round; directed at teaching Hematology/Oncology fellows and Clinical Pathology residents; all aspects of hemostasis and thrombosis with particular attention to laboratory evaluation with clinical correlations

Industry Training

September, 2005 "Outsourcing for Small and Medium-Sized Biotechs" (2 Days) IBC
April, 2005 "Biological Drug Development" (2 Days) PERI
February, 2005 "Follow on Protein Pharmaceuticals" (2 1/2 days) Drug Information Association
February, 2005 "Investigator Initiated Studies" (2 days) PERI
November, 2004 "Update on International Regulatory Issues related to Drug Development" (2 days) Barnett International
October, 2004 "Thought Leaders and Key Opinion Leader (KOLs)" (2 days) Center for Business Intelligence
January, 2004 "Phase IV Clinical Trials" (2 days) Barnett International
November, 2003 "Expedited Drug Approval Pathways" (2 days)Barnett International
February, 2003 "Improving Product Development in a Changing World" (2 days) Scripps Clinic
November, 2001 "Statistical Concepts for Non-Statisticians" (2 days) Barnett International
October, 2001 "Conducting Clinical Trials Under ICH GCP" (2 days) Barnett International
May, 2001 "Delivery of Drugs by Inhalation" (1 day) Henry Stewart Conference / Georgetown University
October, 2000 "Clinical Trials 2000 Conference" USDA-sponsored (2 days); Pharmaceutical Quality Institute
October, 1999 "Preclinical and Clinical Development of Biologic Therapeutics: Focus on Pharmacokinetics and Pharmacodynamics" FDA/CBER-sponsored (3 days) Georgetown University
July, 1998 "Monitoring Clinical Drug Studies: Beginner" (3 days) Barnett International

Scientific Activities

2003-present Manuscript reviewer for Journal of Thrombosis and Hemostasis
1996-1997 President, VA Society of Hematology/Oncology
Jul. 1996 - May 1998 Program Co-Director, Hematology/Oncology Fellowship Training Program
1994 - 1998 Contributing Editor, Yearbook of Clinical Pathology and Laboratory Medicine
Jul 1994 - Aug. 1996 Co-Principal Investigator, National Institutes of Health - Hematology Training Grant 5 T32 DK07509-10.
Apr. 1994 - Jul. 1996 Program Director, Hematology/Oncology Fellowship Training Program
1993 - 1998 Coordinator, Medical Resident Hematology/Oncology Consult Elective
Apr. 1992 - May 1998 Medical Director, University of VA Adult Hemophilia Treatment Center
1993 - 1998 Coordinator, Medical Student Clinical Hematology/Oncology Elective
1992 - 1993 Member, Residency Program Review Committee, Department of Pathology
Jan. 1992 - May 1998 Internal Medicine representative, University of VA Health Sciences Center Transfusion Committee.
Jul. 1991 - May 1998 Appointee, State of VA Hemophilia Advisory Committee
Jul. 1991 - May 1998 Member, Medical and Scientific Advisory Committee; United VA Chapter of the National Hemophilia Foundation
1991 - 1998 American Journal of Clinical Pathology, American Journal of Medical Sciences, Anesthesiology, Clinical Chemistry, Annals of Pharmacotherapy, Blood Coagulation and Fibrinolysis, Journal of Critical Illness, Journal of Neurosurgery, Journal of Urology, Nephron, Southern Medical Journal


Invited Lectures

February 20, 2007 "Antithrombin III in the ICU: Failure to Launch" Society of Critical Care Medicine, Orlando, FL.
September 23, 2004 "Coagulopathies and DIC" Neurology Critical Care Conference, Charlottesville, VA.
September 10, 2004 "ALTA Program" Evening Symposium, European Respiratory Society, Glasgow, Scotland.
April 4, 2000 "Antithrombin Concentrates: Role in Cardiopulmonary Bypass" Surgery Grand Rounds, Washington Hospital Center, Washington, DC.
September 19, 1998 "Bigger Isn't Always Better: Clinical Uses of Low Molecular Weight Heparins" Coagulation Continuing Medical Education Course, Medical College of VA, Richmond, VA.
September 18, 1998 "Hypercoagulable Disorders: Diagnosis and Treatment" The Charles J. Tegtmeyer, MD, Memorial Continuing Medical Education Course, Charlottesville, VA.
September 18, 1998 "Low Molecular Weight Heparins for Treatment and Prophylaxis for Venous Thromboembolic Disease" The Charles J. Tegtmeyer, MD, Memorial Continuing Medical Education Course, Charlottesville, VA.
May 2, 1998 "Low Molecular Weight Heparin, New Treatment" 46th Annual Scientific Assembly of the WV Chapter of the American Academy of Family Physicians, Charleston, WV.
April 9, 1998 "Low Molecular Weight Heparins: Role in the Treatment of Thromboembolism" Shenandoah Memorial Hospital Continuing Medical Education Conference, Woodstock, VA.
March 31, 1998 "Update on the Use of Low Molecular Weight Heparins" Medical Grand Rounds, Porstmouth Naval Hospital, Portsmouth, VA.
March 13, 1998 "Low Molecular Weight Heparins: Indications and Contraindications" Roanoke Memorial Hospital 49th Annual Postgraduate Program, Roanoke, VA.
March 6, 1998 "Outpatient Treatment of Venous Thromboembolism" Salem Veterans Administration Hospital Medical Staff Conference, Salem, VA.
March 6, 1998 "Review of Hemostasis" Roanoke Memorial Hospital Grand Rounds, Roanoke, VA.
February 27, 1998 "Use of Low Molecular Weight Heparins in the Prevention of Thromboembolism" Mary Washington Hospital Medical Staff Conference, Fredericksburg, VA.
February 24, 1998 "Update on the Treatment of Deep Vein Thrombosis and Pulmonary Embolism" Lewis-Gale Clinic Continuing Medical Education Program, Salem, VA.
February 19, 1998 "Use of Low Molecular Weight Heparin in Unstable Angina and Arterial Thrombosis" Bluefield Regional Medical Center Continuing Medical Education Program, Bluefield, WV.
November 20, 1997 "Use of Low Molecular Weight Heparin for the Treatment of Deep Vein Thrombosis" Sentara VA Beach Hospital Continuing Medical Education Course, VA Beach, VA.
November 8, 1997 "Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin" Scientific Session of the Annual Meeting of the Medical Society of VA, Hot Springs, VA.
October 14, 1997 "New Agents in the Treatment of Thrombosis" Annual Update in Clinical Medicine, Charlottesville, VA.
June 26, 1997 "Use of Low Molecular Weight Heparin in the Treatment of Deep Vein Thrombosis" Bluefield Medical Society Continuing Medical Education Conference, Bluefield, WV
April 14, 1997 "Update on Hemostasis and Thrombosis" Hematology Rounds, Veterans Administration Hospital, Salem, VA.
April 14, 1997 "Case Studies in Hemostasis and Thrombosis" Annual Meeting of VA Society of Medical Technology, Roanoke, VA.
March 27, 1997 "Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin" Medical Staff Rounds, Pulaski General Hospital, Pulaski, VA.
November 7, 1996 "Antithrombin III in the Treatment of Disseminated Intravascular Coagulation" Baylor Division of Hematology Conference, Houston, TX.
August 28, 1996 "Treatment of Disseminated Intravascular Coagulation: Role of Antithrombin III Concentrates" Hematology/Oncology Grand Rounds, University of Miami Medical Center, Miami, FL.
July 30, 1996 "Role of Antithrombin III in the Treatment of Disseminated Intravascular Coagulation" Critical Care Grand Rounds, Howard University Medical Center, Washington, DC.
July 17, 1996 "Update on the Management of Disseminated Intravascular Coagulation" Winchester Medical Center Grand Rounds, Winchester, VA.
April 26, 1996 "Update on Hypercoagulable States: Activated Protein C Resistance" Medical Grand Rounds, Roanoke Memorial Hospital, Roanoke, VA.
April 23, 1996 "Antithrombin III Concentrates: Use in the Treatment of Disseminated Intravascular Coagulation" Intensive Care Clinical Conference, St. Louis, MO.
April 23, 1996 "Role of Antithrombin III in the Treatment of Disseminated Intravascular Coagulation" Medical Grand Rounds, Baptist Medical Center, Kansas City, KS.
April 4, 1996 "Update on the Treatment of Inherited Bleeding Disorders" Medical Grand Rounds, Bethesda Naval Hospital, Bethesda, MD
March 2, 1996 "Treatment of Acquired Coagulation Disorders" Augusta Medical Center Grand Rounds, Fishersville, VA
December 20, 1995 "Update on Hypercoagulable States: Activated Protein C Resistance" Medical Grand Rounds, Winchester Medical Center, Winchester, VA.
November 8, 1995 "Treatment of Disseminated Intravascular Coagulation: the Role of Antithrombin III Concentrates" Medical Grand Rounds, Trinity Lutheran Hospital, Kansas City, MO.
November 7, 1995 "Update on the Prophylaxis and Treatment of Deep Vein Thrombosis" Hospital Grand Rounds, Richmond Memorial Hospital, Richmond, VA.
October 8, 1995 "Treatment of Disseminated Intravascular Coagulation: the Role of Antithrombin III Concentrates" Critical Care Continuing Medical Education Program, Syracuse, NY.
September 11, 1995 "Treatment of Disseminated Intravascular Coagulation: the Role of Antithrombin III Concentrates" Critical Care Grand Rounds, Hahneman University, Philadelphia, PA.
June 10, 1995 "The Use of Natural Anticoagulants to Normalize Hemostasis in Disseminated Intravascular Coagulation" New Concepts in Critical Care Medicine Conference, Georgetown University, Washington, DC
May 2, 1995 "Management of Disseminated Intravascular Coagulation" Department of Medicine Grand Rounds, Washington General Hospital, Washington, DC.
March 9, 1995 "Update on the Prophylaxis and Treatment of Deep Vein Thrombosis" Bluefield Medical Society Continuing Medical Education Program, Bluefield, WV.
February 7, 1995 "Prophylaxis and Treatment of Deep Vein Thrombosis" Martha Jefferson Hospital Continuing Medical Education Program, Charlottesville, VA.
January 27, 1995 "Update on the Prophylaxis and Treatment of Deep Vein Thrombosis" Continuing Medical Education Conference, Health South Medical Center, Richmond, VA.
January 21, 1995 "Antithrombin III: Mechanisms of Regulation of Hemostasis and its Therapeutic Role in the Treatment of DIC" Current Concepts in Hemostasis and Thrombosis, University of California - Davis, Sacramento, CA.
January 20, 1995 "The Role of Antithrombin III in Disseminated Intravascular Coagulation" Critical Care Medicine Conference, San Francisco General Hospital, San Francisco, CA.
January 20, 1995 "Antithrombin III: Mechanisms of Regulation of Hemostasis and its Therapeutic Role in the Treatment of DIC" Intensive Care Unit Morning Conference, University of California - San Francisco, San Francisco, CA.
January 19, 1995 "Antithrombin III: Role in the Management of DIC" Anesthesia Clinical Conference, San Francisco, CA.
December 8, 1994 "Clinical Use of Low Molecular Weight Heparin" Orthopaedic Surgery Group, Roanoke, VA.
November 22, 1994 "DIC and Sepsis: Role of Antithrombin III" Allegheny General Hospital, Pittsburgh, PA.
October 22, 1994 "Thrombophilia and Acquired Complex Deficiencies of Antithrombin, Protein C and Protein S" National Antithrombin Investigators Conference, Phoenix, AZ.
October 3, 1994 "Management of Disseminated Intravascular Coagulation: Role of Antithrombin III Concentrates" Hematology Grand Rounds, The Johns Hopkins Hospital, Baltimore, MD
September 9, 1994 "Antithrombin III Concentrate and the Management of DIC" Critical Care Grand Rounds, Mount Sinai Medical Center, New York, NY.
September 7, 1994 "Management of DIC:Present and Future" Medical Grand Rounds, St. Luke's/Roosevelt Hospital, New York, NY.
September 7, 1994 "Management of Disseminated Intravascular Coagulation: Role of Antithrombin III Concentrates" Critical Care Grand Rounds, St. Luke's/Roosevelt Hospital, New York, NY.
August 18, 1994 "Recent Developments in the Management of Disseminated Intravascular Coagulation." Department of Medicine Grand Rounds, Albany School of Medicine, Albany, NY.
July 14, 1994 "Deep Vein Thrombosis: Update on Treatment and Prophylaxis" Medical Ground Rounds, Southside General Hospital, Petersburg, VA.
June 25, 1994 "Clinical Experience in the Management of Acquired Antithrombin III Deficiency" Current Topics in Hematology/Oncology Conference, Washington, DC.
May 18, 1994 "Overview of Hemostasis and Thrombosis" Conference on the Contribution of Coagulation Abnormalities to Sepsis. Williamsburg, VA.
May 11, 1994 "Deep Vein Thrombosis: Update on Treatment and Prophylaxis" Rockingham Memorial Hospital Continuing Medical Education Course, Harrisonburg, VA.
December 15, 1993 "Clinical Uses of Antithrombin III Concentrates" Medicine Grand Rounds, Norfolk General Hospital, Norfolk, VA.
October 7, 1993 "Approach to the Patient with Mild Bleeding Symptoms" 20th Annual Recent Advances in Clinical Medicine, University of VA, Charlottesville, VA.
August 31, 1993 "Hemostasis and Thrombosis Update" a series of lectures (3), Salem Veterans Administration Hospital, Salem, VA.
January 20, 1993 "The INR: To Use or Not to Use" VA Society of Medical Technology, Fredericksburg, VA.
October 20, 1992 "Regulation of Fibrinolysis" Clinical Hemostasis and Thrombosis Rounds, Duke University, Durham, NC.
April 14, 1992 "Hemostasis and Thrombosis" a series of lectures (6) given as a day-long symposium; Salem Veterans Administration Hospital, Salem, VA
October 11, 1991 "Evaluation of Thrombotic Disorders" 18th Annual Recent Advances in Clinical Medicine, University of VA, Charlottesville, VA
January 17, 1991 "Fibrinolysis and the Plasminogen Receptor" Texas A&M University, Scott & White Clinic, Temple, Texas

Memberships in Professional Societies

2007 - present European Association for the Study of Liver Diseases
2006 - present Vascular Access Society of the Americas
2005 - present Drug Information Association
2002 - present Cardiovascular and Interventional Radiology Society of Europe
2001 - present European Cystic Fibrosis Society
2000 - present Society of Interventional Radiology
1999 - present European Respiratory Society
1999 - present American Thoracic Society
1998 - 2002 American Association of Blood Banks
1997 - present Fellow of the Council on Arteriosclerosis, Thrombosis, and Vascular Biology, of the American Heart Association
1996 - present Academy of Clinical Laboratory Physicians and Scientists
1994 - 2004 International Academy of Clinical and Applied Thrombosis/Hemostasis
1993 - present International Society on Thrombosis and Haemostasis
1993 - present International Society on Fibrinolysis
1992 - present Fellow, American College of Physicians
1992 - 1997 American Heart Association, Thrombosis Council
1991 - present American Society of Hematology
1991 - 1998 Albemarle County Medical Society
1990 - 1998 Virginia Chapter of the National Hemophilia Foundation
1990 - 1993 Medical Society of Virginia
1989 - present National Hemophilia Foundation
1989 - 1998 American Federation for Clinical Research

Grant Support

  • NIH Physician Scientist Award HL-02592. "Hepatic Mechanisms in the Regulation of Fibrinolysis" Principal Investigator. Funded 5/1/91 - 4/30/96 (5 years): $66,528 1st year; $419,288 total award.
  • Cancer Center Clinical Research Grant. "Low-dose Coumadin for the Prevention of Thrombosis in Long-term Indwelling Catheters in Patients with Malignancy" Funded 7/1/95-6/30/96; $20,000.
  • Research and Development Committee Grant, University of Virginia. "Recombinant alpha-2-antiplasmin" Funded 7/1/97 - 6/30/98; $13,000.

Peer Review Participation

  • Site-visit reviewer for NIH Program Project: University of Rochester, February, 1993.

Publications:

Published Manuscripts in Refereed Journals

  1. de Leede L, Humphries JE, Bechet A, van Hoogdalem E, Verrijk R, Spencer D: Novel controlled-release Lemna-derived interferon alpha2b (Locteron): Pharmacokinetics, Pharmacodynamics and Tolerability in a phase I clinical trial. J Interferon Cytokine Res: (in Press).
  2. Sadeghi S, Marder VJ, Stewart D, Kong M, Humphries J, Baumbach GA, Jesmok G: Safety of plasmin in the setting of concomitant aspirin and heparin administration in an animal model of bleeding. J Thromb Haemost 1:2621-2625, 2003.
  3. Winther B, Gwaltney Jr JM, Humphries JE, Hendley JO: Cross-linked fibrin in nasal fluid of patients with the common cold. Clin Infect Dis 34:708-710, 2002.
  4. Stanley TB, Humphries J, High KA, Stafford DW: Amino acids responsible for reduced affinities of vitamin K-dependent propeptides for the carboxylase. Biochemistry 38:15681-15687, 1999.
  5. Bishop